New findings presented at #ASCO26 suggest a new approach could help slow the growth of intermediate-stage liver cancer. An international phase 3 clinical trial led by MSK's Dr. Ghassan K. Abou-Alfa (@GABOUALFA) found that adding dual immunotherapy to TACE significantly increased progression-free survival for people with hepatocellular carcinoma (HCC). “By combining dual immunotherapy with TACE, we give patients a better chance of living longer while preserving a healthy, working liver.” Learn more: bit.ly/4x7vt7o

Proud to see 18 MSK staff recognized as 2026 Conquer Cancer Grants & Awards recipients ahead of #ASCO26. Congratulations to this outstanding group helping advance the future of cancer research and care. 👏

⚠️ New MSK research presented at #AACR26: A drug given “breakthrough designation” by @US_FDA may offer the best new option in many years for people facing #pancreaticcancer. #Daraxonrasib targets mutations in the RAS gene, which helps control cell growth — these mutations send signals that fuel cancer cells. #KRAS is the most common of these mutations and drives over 90% of pancreatic cancer, which is projected to be the second most deadly cancer in the U.S. by 2030. MSK gastrointestinal medical oncologist @EileenMOReilly led a phase 1/2 clinical trial of daraxonsarib as part of a larger multidisease trial led by thoracic medical oncologist Dr. @KCArbourMD. In Dr. O’Reilly’s trial, the patients with pancreatic cancer had not yet received any form of treatment. “This drug is potentially going to be a landmark shift in how we treat pancreatic cancer,” says Dr. O'Reilly. “The ability to target RAS mutations that drive so much of pancreatic cancer is huge and has been missing from our treatments.” Learn more about this research: bit.ly/4trr1xK @AACR